pozanicline
Pozanicline is a drug developed by Abbott, that has nootropic and neuroprotective effects. Animal studies suggested it useful for the treatment of ADHD and subsequent human trials have shown ABT-089 to be effective for this application. It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class. — Wikipedia
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2003 (NCT00069849)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Neuronal acetylcholine receptor; alpha6/beta2PARTIAL AGONIST
Neuronal acetylcholine receptor; alpha6/beta2 partial agonist
- Nicotinic acetylcholine receptor alpha4/beta2/alpha5PARTIAL AGONIST
Nicotinic acetylcholine receptor alpha4/beta2/alpha5 partial agonist
Chemistry & pharmacology
SMILES
Cc1ncccc1OC[C@@H]1CCCN1- Mol. weight
- 192.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPozanicline ↗
- ChEMBLCHEMBL127071 ↗
Also known as
- 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (r)-isomer
- 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (s)-isomer
- 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine, (s)-isomer
- a-87089.0
- a-87089.0
- abt 089
- abt-089
- abt-089
- abt-089
- abt-089
- pozanicline
- pozanicline
- pozanicline
- pozanicline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01756053 | Phase 2 | Mar 1, 2013 | University of Pennsylvania |
| NCT00809510 | Phase 2 | Jan 1, 2009 | Abbott |
| NCT00686933 | Phase 2 | May 1, 2008 | AbbVie |
| NCT00640419 | Phase 2 | Mar 1, 2008 | AbbVie |
| NCT00640185 | Phase 2 | Mar 1, 2008 | AbbVie |
| NCT00555204 | Phase 2 | Nov 1, 2007 | Abbott |
| NCT00554385 | Phase 2 | Nov 1, 2007 | Abbott |
| NCT00528697 | Phase 2 | Sep 1, 2007 | AbbVie |
| NCT00443391 | Phase 2 | Feb 1, 2007 | AbbVie |
| NCT00391729 | Phase 2 | Oct 1, 2006 | Abbott |
| NCT00069849 | Phase 2 | Jul 1, 2003 | Abbott |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 5 | 5 | 1 | 2003 |
| AbbVie | For profit | 5 | 5 | 1 | 2007 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2013 |